Berlin, Germany

Nicole Dinse

USPTO Granted Patents = 8 


 

Average Co-Inventor Count = 7.2

ph-index = 3

Forward Citations = 17(Granted Patents)


Company Filing History:


Years Active: 2012-2018

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Innovations by Nicole Dinse in Cancer Treatment

Introduction

Nicole Dinse is a prominent inventor based in Berlin, Germany. She has made significant contributions to the field of cancer treatment through her innovative research and development of nucleic acid molecules. With a total of 8 patents to her name, Dinse is recognized for her groundbreaking work in the medical and pharmaceutical industries.

Latest Patents

Among her latest patents, Dinse has developed nucleic acid molecules capable of binding to SDF-1, which is crucial in cancer treatment. One of her notable inventions is related to a nucleic acid molecule that can inhibit SDF-1, making it useful in methods for treating or preventing diseases, particularly cancer. Another patent focuses on a nucleic acid molecule that influences the migration of cells, further enhancing the potential for therapeutic applications in oncology.

Career Highlights

Dinse's career is marked by her dedication to advancing cancer therapies. She works at Noxxon Pharma AG, where her research is pivotal in developing innovative treatments. Her expertise in nucleic acid technology has positioned her as a leader in her field, contributing to the ongoing fight against cancer.

Collaborations

Some of her notable coworkers include Sven Klussmann and Klaus Buchner, who collaborate with her on various projects aimed at enhancing cancer treatment methodologies.

Conclusion

Nicole Dinse's contributions to cancer treatment through her innovative patents highlight her role as a leading inventor in the medical field. Her work continues to inspire advancements in therapeutic approaches, making a significant impact on patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…